Intravitreal Bevacizumab for Age-Related Macular Degeneration
NCT ID: NCT00347165
Last Updated: 2024-05-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
50 participants
INTERVENTIONAL
2005-09-30
2006-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration
NCT00347399
Bevacizumab and Retinal Vascular Occlusions
NCT00347711
Efficacy of Retreatments With Intravitreal Bevacizumab
NCT00406744
Intravitreal Bevacizumab vs Photocoagulation for Proliferative Diabetic Retinopathy
NCT00347698
Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration
NCT00556348
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The purpose of this study is efficacy and safety of 2.5 mg intravitreal of bevacizumab for AMD
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
bevacizumab intravitreal injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
50 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Asociación para Evitar la Ceguera en México
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hugo Quiroz-Mercado, MD
Role: STUDY_CHAIR
Asociación para Evitar la Ceguera en México
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Luis Sanchez Bulnes
Mexico City, Mexico City, Mexico
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):331-5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AvastinDMRE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.